Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1999-01-12
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 9463, 424 9464, A61K 3817
Patent
active
058589694
ABSTRACT:
Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.
REFERENCES:
patent: 5256642 (1993-10-01), Fearon et al.
patent: 5456909 (1995-10-01), Marsh et al.
Mulligan et al., 1992, "Lung Injury After Deposition of IgA Immune Complexes," J. Immunol. 148:3086-3092.
Mulligan et al., 1992, "Protective Effects of Soluble CR1 in Complement and Neutrophil-Mediated Tissue Injury", J. Immunol 148:1479-1485.
Pruitt et al., 1991, "The Effect of Soluble Complement Receptor Type 1 on Hyperacute Xenograft Rejection," Transplantation 52:868-873.
Pruitt and Bolinger, 1991, "The Effects of Soluble Complement Receptor Type 1 on Hyperacute Allograft Rejection," J. Surg. Res. 50:350-355.
Yeh et al., 1991, "Recombinant Soluble Human Complement Receptor Type 1 Inhibits Inflammation In The Reversed Passive Arthus Reaction in Rats," J. Immunol. 146:250-256.
Weisman et al., 1990, "Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post Ischemic Myocardial Inflammation and Necrosis," Science 249:146-151.
Yoon and Fearon, 1985, "Chacterization of a Soluble Form of the C3b/C4b receptor (CR1) In Human Plasma," J. Immunol. 134:3332-3338.
Krych et al., 1989, "A Secreted Small Form of Human Complement C3b/C4b Receptor (CR1) that Binds to C4b But Not C3b," F.A.S.E.B. J. 3:A368.
Klickstein et al., 1988, "Identification of Distinct C3b and C4b Recognition Sites in the Human C3b/C4b Receptor (CR1, CD35) By Deletion Mutagenesis," J. Exp. Med. 168:1699-1717.
Hourcade et al., 1988, Identification of an Alternative Polyadenylation Site in the Human C3b/C4b Receptor (Complement Receptor Type 1) Transcriptional Unit and Prediction of a Secreted Form of Complement Receptor Type 1, J. Exp. Med. 168:1255-1270.
Klickstein et al., 1987, "Human C3b/C4b Receptor (CR1)," J. Exp. Med. 165:1095-1112.
Wong et al., 1985, "Rapid Purification of the Human C3b/C4b Receptor (CR1) by Monoclonal Antibody Affinity Chromatography," J. Immunol. Methods 82:303-313.
Lublin et al., 1986, "Influence of Glycosylation on Allelic and Cell-specific Mr. Variation, Receptor Processing, and Ligand Binding of the Human Complement C3b/C4b Receptor," J. Biol. Chem. 261:5736.
Sim, 1985, "Large-Scale Isolation of Complement Receptor Type 1 (CR1) From Human Erythrocytes," Biochem J. 232:883-889.
Skubitz and Snook, 1987, "Monoclonal Antibodies That Recognize Lacto-N-Fucopentaose III (CD 15) React With the Adhesion-Promoting Glycoprotein Family (LFA-1/HMAC-1/GP 150,95) and CR1 On Human Neutrophils," J. Immunol. 139:1631-1639.
West, 1986, "Current Ideas on the Significance of Protein Glycosylation," Mol. Cell. Biochem. 72:3-20.
Goochee and Monica, 1990, "Environmental Effects on Protein Glycosylation," Bio/Technology 8:421-427.
Takenchi et al., 1988, "Comparative Study of the Asparagine-linked Sugar Chains of Human Erythroproteins Purified from Urine and the Culture Medium of Recombinant Chinese Hamster Ovary Cells", J. Biol. Chem. 263:3657-3663.
Parekh et al., 1989, "N-glycosylation and the production of recombinant glycoproteins", Trends in Biotechnol. 7: 117-122.
Makrides et al. 1992, "Cell Surface Expression of the C3b/C4b Receptor (CR1) Protects Chinese Hamster Ovary Cells from Lysis by Human Complement," J. Biol. Chem. 267:24754-24761.
Stanley et al., 1988, "The LEC11 Chinese Hamster Ovary Mutant Synthesized N-Linked Carbohydrates Containing Sialylated, Fucosylated Lactosamine Units," J. Biol. Chem. 263:11374-11381.
Paulson, 1989, "Glycoproteins: what are the sugar chains for?" Trends In Biochem. Sci. 14:272-276.
Goochee et al., 1991, "The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligosaccharide Structure and Their Effect on Glycoprotein Properties," Biotechnology 9:1347-1355.
Kobata, Akira, 1992, "Structures and Functions of the Sugar Chains of Glycoproteins," Eur. J. Biochem. 209:483-501.
Freeman Anne Mary
Gosselin Michael L.
Lifter John
Marsh, Jr. Henry C.
Smith Richard A.G.
Fitzgerald David L.
T Cell Sciences, Inc.
Yankwich Leon R.
LandOfFree
Therapeutic methods employing sialylated glycoforms of soluble c does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods employing sialylated glycoforms of soluble c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods employing sialylated glycoforms of soluble c will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1515921